Immunovant, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Immunovant, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-885.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-5,657.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+15%Cash, after subtracting all debt, equals 15% of its market value (net cash).
Higher than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Immunovant, Inc. made a loss over the last year. Immunovant, Inc. owes $0.14 for every $1 it owns. Immunovant, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
LossImmunovant, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.17The share price is 8.17 times Immunovant, Inc.'s book value per share, higher than 83% of Healthcare companies in United States.
Market cap
$6.0 BThe total market value of all of Immunovant, Inc.'s shares at today's price (share price × number of shares), larger than 86% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$735 MWhat Immunovant, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.56Net worth divided by the number of shares. The share price of $29.10 is 8.2 times this, which is the P/B above.
Return on equity (ROE)
-80.1%Immunovant, Inc. lost 80.1% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
Owes vs Owns
0.14×Immunovant, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
NoneImmunovant, Inc. does not currently pay a dividend.
Profit growth
LossImmunovant, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashImmunovant, Inc. held $902 M more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Immunovant, Inc.: $6.0 B ÷ $735 M (30 Jun 2026) = 8.2.
What is Immunovant, Inc.'s return on equity?
Immunovant, Inc. lost 80.1% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
How much does Immunovant, Inc. owe compared with what it owns?
Immunovant, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does Immunovant, Inc. pay a dividend?
No. Immunovant, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.